|

Title: Methods for treating a fibrin encapsulated tumor
using a fibrin specific monoclonal antibody and compositions used therein
United States Patent: 6,187,593
Inventors: Gargan; Paul E. (Southbend, IN); Ploplis; Victoria
A. (Leuven, BE); Pleasants; Julian R. (Granger, IN)
Assignee: American Biogenetic Sciences, Inc. (Copiague,
NY)
Appl. No.: 207913
Filed: December 9, 1998
Abstract
The subject invention relates a method for the production of monoclonal
antibodies. The method utilizes an immunized germfree animal. The
invention also provides methods for the use of such monoclonal antibodies,
and polyclonal antibodies derived from an immunized germfree animal, for
in vitro and in vivo clinical diagnostics and therapeutics. Also, the
subject invention provides a fibrin-specific monoclonal antibody.
SUMMARY OF THE INVENTION
The subject invention provides a method for the production of monoclonal
antibodies to an antigen comprising:
(a) immunizing a germfree animal with said antigen to permit
antibody-producing cells to produce antibodies to said antigen,
(b) removing at least a portion of said antibody-producing cells from said
germfree animal,
(c) forming a hybridoma by fusing one of said antibody-producing cells
with an immortalizing cell wherein said hybridoma is capable of producing
a monoclonal antibody to said antigen,
(d) propagating said hybridoma, and
(e) harvesting the monoclonal antibodies produced by said hybridoma.
The subject invention also provides methods for utilizing a monoclonal
antibody or a polyclonal antibody derived from a germfree animal. The
subject invention also provides a fibrin-specific monoclonal antibody and
methods for utilizing such a monoclonal antibody.
Claim 1 of 7 Claims
We claim:
1. A method for utilizing a monoclonal antibody in conjugation with a
cytotoxic reagent for the treatment of a fibrin encapsulated tumor
comprising administering to a human in need of said treatment a monoclonal
antibody in conjugation with a cytotoxic reagent, the improvement
comprising employing for said monoclonal antibody a fibrin-specific
monoclonal antibody that is MH-1 produced by hybridoma ATCC 9739 or an
immunoreactive fragment thereof, or an antibody or an immunoreactive
fragment thereof that competitively inhibits the immunospecific binding of
the MH-1 antibody produced by hybridoma ATCC HB 9739 to MH-1's target
antigen.
____________________________________________
If you want to learn more
about this patent, please go directly to the U.S.
Patent and Trademark Office Web site to access the full
patent.
|